With many of the usual targets on display Fate, Celyad, Allovir and others look to maintain momentum.
Unveiling of abstracts for December’s haematology meeting sent Crispr up and Allogene down, but the biggest beneficiary was private.
A patient death overshadowed the first data from a human trial of the company’s allogeneic Car-T therapy CTX110.